

Contact: Julie Miller
Phone: 310-437-0544, Ext. 179
Email: julie@sages.org



FOR IMMEDIATE RELEASE

SAGES Ingenuity's SINC Fund and Varia Ventures Invest in Geneoscopy's Series C to Advance Gastrointestinal Diagnostic Innovation

May 1, 2025 - Los Angeles, Calif. – The SINC Fund, a venture capital fund sponsored by SAGES Ingenuity Inc. (<https://www.sages-ingenuity.com>), a for-profit entity formed to invest in and accelerate innovation, and Varia Ventures Management Company, LLC (<https://www.varia.com>), a venture capital firm, is pleased to announce an investment in Geneoscopy, Inc. This investment underscores the Fund's commitment to supporting groundbreaking technologies that improve patient care and advance the field of gastrointestinal health.

Geneoscopy, a life sciences company, is focused on developing innovative diagnostic tests for gastrointestinal diseases, most notably the company's FDA-approved ColoSense® test, a non-invasive, stool-based colorectal cancer screening test. The company's technology platform utilizes proprietary RNA biomarker analysis to provide accurate and reliable diagnostic information to screen for cancer and precancerous polyps (advanced adenomas). The Series C funding will support the commercial launch of ColoSense and advance research into diagnostic testing for inflammatory bowel disease.

"Geneoscopy's ColoSense test represents a significant leap forward in non-invasive colorectal cancer screening," said SD Schwaitzberg, MD, FACS, Chair of the SINC Fund Investment Committee. "By providing accurate and accessible diagnostic information, Geneoscopy empowers both patients and physicians to take proactive steps in managing gastrointestinal health. We are proud to support their mission through the SINC Fund."

"Having the SINC Fund join our Series C funding round is a powerful endorsement of Geneoscopy's technology and mission," said Andrew Barnell, CEO of Geneoscopy. "Their support – especially from members on the front lines of patient experience and gastrointestinal care – reinforces the impact our innovations can have in improving patient outcomes."

The SINC Fund (<https://sincinvest.varia.com/>) was launched to allow SAGES members and others to invest in a venture fund with a portfolio of startups primarily in the therapeutic

GI/GI surgery space. The investment in Geneoscopy aligns with SAGES Ingenuity's mission to foster innovation in surgical and gastroenterological care by providing critical funding and support to promising early-stage companies.

###

About SAGES

The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) is a leading surgical society representing a global community of more than 7,000 surgeons bringing minimal access surgery and emerging techniques to patients worldwide. SAGES mission is to innovate, educate and collaborate to improve patient care with a vision of reimagining surgical care for a healthier world. For more information, go to <https://www.sages.org>.

About Varia Ventures

Varia Ventures is a venture capital firm that partners with globally recognized thought leaders, prestigious medical and surgical societies and others to manage venture funds in their fields of expertise.

About Geneoscopy:

Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics.

Disclaimer:

None of SAGES, SAGES Ingenuity, Varia Ventures or any of their affiliates provides personalized advice about investments, and this content should not be construed or relied on as such. You should consult your own advisers concerning any investment. All content is for informational purposes only. This content does not constitute an offer to sell, or a solicitation of an offer to buy, an interest in any jurisdiction in which it unlawful to make such an offer or solicitation. Offers of securities are made only to accredited investors pursuant to a fund's offering documents, which describe the risks, fees and other information that should be considered before investing. This content may contain forward-looking statements, which should not be relied upon and are not guarantees of future results, performance, achievements or success. Certain information contained herein has been obtained from other parties. While such sources are believed to be reliable, none of SAGES, SAGES Ingenuity, Varia Ventures or any of their affiliates assumes any responsibility for the accuracy or completeness of such information. The information set forth herein does not purport to be complete and no obligation to update or otherwise revise such information is being assumed.